ChiCTR2400081301 版本V1.0 版本创建时间2024/02/28 11:25:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400081301 

最近更新日期:

Date of Last Refreshed on:

2024-02-28 11:25:27 

注册时间:

Date of Registration:

2024-02-28 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

不同血管活性药物预处理对肌少症老年患者全身麻醉诱导期血流动力学的影响

Public title:

Effect of different vasoactive drug premedication on hemodynamics during induction of general anesthesia in elderly patients with sarcopenia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

不同血管活性药物预处理对肌少症老年患者全身麻醉诱导期血流动力学的影响

Scientific title:

Effect of different vasoactive drug premedication on hemodynamics during induction of general anesthesia in elderly patients with sarcopenia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

戎银辉 

研究负责人:

秦再生 

Applicant:

Yinhui Rong 

Study leader:

Zaisheng Qin 

申请注册联系人电话:

Applicant telephone:

+86 183 0091 5307

研究负责人电话:

Study leader's telephone:

+86 134 3424 3868

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ryh1092734123@163.com

研究负责人电子邮件:

Study leader's E-mail:

QZSMZK@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市广州大道北1838号

研究负责人通讯地址:

广东省广州市广州大道北1838号

Applicant address:

1838 Guangzhou Avenue North, Guangzhou, Guangdong, China

Study leader's address:

1838 Guangzhou Avenue North, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学南方医院

Applicant's institution:

Nanfang Hospital, Southern Medical University

研究负责人所在单位:

南方医科大学南方医院

Affiliation of the Leader:

Nanfang Hospital, Southern Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

NFEC-2023-536

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南方医科大学南方医院医学伦理委员会

Name of the ethic committee:

Medical Ethics committee of NanFang Hospital of Southern Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-12-01 00:00:00

伦理委员会联系人:

薛莲

Contact Name of the ethic committee:

Xue Lian

伦理委员会联系地址:

广东省广州市广州大道北1838号

Contact Address of the ethic committee:

1838 Guangzhou Avenue North, Guangzhou, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 6278 7238

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学南方医院

Primary sponsor:

Nanfang Hospital, Southern Medical University

研究实施负责(组长)单位地址:

广东省广州市广州大道北1838号

Primary sponsor's address:

1838 Guangzhou Avenue North, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

南方医科大学南方医院

具体地址:

广州大道北1838号

Institution
hospital:

Nanfang Hospital, Southern Medical University

Address:

1838 Guangzhou Avenue North

经费或物资来源:

研究者自筹

Source(s) of funding:

Self-financed by the researcher

Target disease:

Sarcopenia

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.探讨预先使用血管活性药物是否可以使合并肌肉减少症的老年患者在全身麻醉诱导期间出现低血压的情况减少 ; 2.通过不同血管活性药物组之间对比,进一步探讨哪一种血管活性药物在维持血流动力学稳定方面更有优势  

Objectives of Study:

1. To explore whether pre-administration of vasoactive drugs leads to a reduction in hypotension during induction of general anesthesia in elderly patients with comorbid sarcopenia; 2. To further explore which vasoactive drug is more advantageous in maintaining hemodynamic stability by comparing between different vasoactive drug groups

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)自愿签署知情同意书; (2)65 岁及以上 ; (3)ASA I~III 级患者 ; (4)计划在全身麻醉下接受择期手术 ; (5)符合少肌症诊断标准。

Inclusion criteria

(1) Voluntary informed consent; (2) 65 years old and above; (3) Patients with ASA I~III; (4) Planning elective surgery under general anesthesia; (5) Meeting diagnostic criteria for sarcopenia.

排除标准:

(1)术前受试者有严重心肺功能异常、甲状腺毒症、心脑血管疾病、有心律失常病史、存在其他肝、肾等疾病; (2)术前评估的收缩 (SAP) 或舒张 (DAP) 动脉血压分别大于200mmHg 和110 mmHg ; (3)围术期突发严重并发症 ; (4)困难气道。

Exclusion criteria:

(1) Preoperative subjects with severe cardiorespiratory abnormalities, thyrotoxicosis, cardiovascular disease, history of cardiac arrhythmias, and presence of other hepatic and renal diseases; (2) Preoperative systolic (SAP) or diastolic (DAP) arterial blood pressure greater than 200 mmHg and 110 mmHg, respectively; (3) Sudden and severe perioperative complications; (4) Difficult airway.

研究实施时间:

Study execute time:

From 2023-07-01 00:00:00 To 2024-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-12-01 00:00:00 To 2024-03-31 00:00:00  

干预措施:

Interventions:

组别:

B组

样本量:

30

Group:

Group B

Sample size:

干预措施:

在诱导同时给予泵注去甲肾上腺素

干预措施代码:

Intervention:

Pumped norepinephrine was given at the same time as induction

Intervention code:

组别:

C组

样本量:

30

Group:

Group C

Sample size:

干预措施:

在诱导同时给予麻黄碱

干预措施代码:

Intervention:

Ephedrine was given at the same time as induction

Intervention code:

组别:

A组

样本量:

30

Group:

Group A

Sample size:

干预措施:

诱导开始静脉泵注生理盐水

干预措施代码:

Intervention:

Saline was given at the same time as induction

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China 

Province:

Guangdong 

City:

Guangzhou 

单位(医院):

南方医科大学南方医院  

单位级别:

三甲医院  

Institution
hospital:

Nanfang Hospital, Southern Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血压

指标类型:

主要指标

Outcome:

Blood pressure

Type:

Primary indicator

测量时间点:

诱导前3分钟、插管前、插管即刻、插管后3分钟、5分钟、10分钟、 15分钟

测量方法:

无创袖带监测和有创动脉监测

Measure time point of outcome:

3 minutes before induction, before intubation, immediately after intubation, 3 minutes, 5 minutes, 10 minutes, 15 minutes after intubation

Measure method:

Noninvasive cuff monitoring and invasive arterial monitoring

指标中文名:

心率

指标类型:

次要指标

Outcome:

Heart rate

Type:

Secondary indicator

测量时间点:

诱导前3分钟、插管前、插管即刻、插管后3分钟、5分钟、10分钟、 15分钟

测量方法:

心电监护仪

Measure time point of outcome:

3 minutes before induction, before intubation, immediately after intubation, 3 minutes, 5 minutes, 10 minutes, 15 minutes after intubation

Measure method:

electrocardiogram (ECG) monitor

指标中文名:

动脉血气分析

指标类型:

次要指标

Outcome:

Arterial blood gas analysis

Type:

Secondary indicator

测量时间点:

入手术室后和插管后15分钟

测量方法:

血气分析仪

Measure time point of outcome:

Upon entering the operating room and 15 minutes after intubation

Measure method:

blood gas analyzer

指标中文名:

脉搏氧饱和度

指标类型:

次要指标

Outcome:

Pulse Oximetry Saturation

Type:

Secondary indicator

测量时间点:

诱导前3分钟、插管前、插管即刻、插管后3分钟、5分钟、10分钟、 15分钟

测量方法:

脉搏血氧饱和度检测仪

Measure time point of outcome:

3 minutes before induction, before intubation, immediately after intubation, 3 minutes, 5 minutes, 10 minutes, 15 minutes after intubation

Measure method:

Pulse Oximetry Monitor

指标中文名:

低血压发生率

指标类型:

主要指标

Outcome:

Incidence of hypotension

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼气末二氧化碳

指标类型:

主要指标

Outcome:

End-expiratory carbon dioxide

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后苏醒状态

指标类型:

主要指标

Outcome:

Postoperative Awakening Status

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究者使用电脑随机分组生成器产生

Randomization Procedure (please state who generates the random number sequence and by what method):

Generated by the researcher using a computerized random group generator

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

单盲,对受试者设盲,评估者不设盲

Blinding:

Single-blind, Subjects blinded, evaluator unblinded

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan, http://www.medresman.org.cn/login.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org.cn/login.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-02-28 11:25:27